Narrative CV

Dr. Shu-Yi Hsieh is an Assistant Research Specialist specializing in chemical synthesis. Her research interests focus on the synthesis of small molecule drugs and nanoparticles, and she is dedicated to advancing knowledge and innovation in this area. She obtained her Ph.D. degree from the Department of Chemistry at National Tsing Hua University and has contributed to multiple research projects. In addition to her professional skills, she is also responsible for the construction and maintenance of RCAS's core facilities, providing excellent component manufacturing and analysis services. Moreover, she manages the experimental safety of her colleagues at the center and ensures safety measures are implemented in all laboratories.

She is developing an automated chemical synthesis system, with the main goal of applying it to small molecule drug research and having a significant impact on drug development.

She actively collaborates with researchers across various disciplines and has made contributions to several interdisciplinary projects.

In the future, she will continue to strengthen the operations and maintenance of core facilities to provide effective micro- and nano-fabrication services. Her future research will focus on advancing automated chemical synthesis and fostering interdisciplinary collaborations. She is committed to translating academic discoveries into real-world applications, ensuring a lasting impact on both academia and society.

Education

• B.A., Department of Chemistry, Tung Hai University, Taichung, Taiwan (2001)
• M.S. in Department of Chemistry, National Taiwan Normal University, Taipei, Taiwan (2003)
• Ph.D. in Department of Chemistry, National Tsing Hua University, Hsinchu, Taiwan (2008)

Positions and Career

• Assistant Research Specialist, Research Center for Applied Sciences, Academia Sinica (2020-)
• Postdoctoral Research, Research Center for Applied Sciences, Academia Sinica (2011-2020)
• Postdoctoral Research, Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, (2080-2011)

Selected Publications

• S. H. Wang, S. C. Y. J. Tung, C. W. Kuo, Y. H. Tai, S. Y. Hsieh, K. L. Lee, S. R. Hsiao, J. F. Sheen, J. C. Hsu and P. K. Wei. "Multichannel Nanoplasmonic Platform for Imidacloprid and Fipronil Residues Rapid Screen Detection Biosensors and Bioelectronics or its open access mirror" Biosens. Bioelectron. 2020, 170, 112677.
• S. H. Wang, C. W. Lee, M. Y. Pan, S. Y. Hsieh, F. G. Tseng, and P. K. Wei. "Chromatogram analysis on revealing aggregated number and location of gold nanoparticles within living cells." Plasmonics, 2015, 10 (4), 873-880.
• W. H. Lin, T. K. Yeh, W. T. Jiaang, K. J. Yen, C. H. Chen, C. T. Huang, S. C. Yen, S. Y. Hsieh, L. H. Chou, C. P. Chen, C. H. Chiu, L. C. Kao, Y. S. Chao, C. T. Chen, and J. T. A. Hsu. & Chiu, C. H. "Evaluation of the antitumor effects of BPR1J-340, a potent and selective FLT3 inhibitor, alone or in combination with an HDAC inhibitor, vorinostat, in AML cancer." PloS one, 2014, 9 (1), e83160
• S. H. Wu, S. Y. Hsieh, K. L. Lee, R. H. Weng, A. Chiou, and P. K. Wei, "Cell viability monitoring using Fano resonance in gold nanoslit array." Applied Physics Letters, 2013, 103 (13), 133702.
• W. H. Lin, J. T. A. Hsu, S. Y. Hsieh, C. T. Chen, J. S. Song, S. C. Yen, T. Hsu, C. T. Lu, C. H. Chen, L. H. Chou, Y. N. Yang, C. H. Chiu, C. P. Chen, Y. J. Tseng, K. J. Yen, C. F. Yeh, Y. S. Chao, T. K. Yeh, and W. T. "Discovery of 3-phenyl-1H-5-pyrazolylamine derivatives containing a urea pharmacophore as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3)." Jiaang, Bioorganic & medicinal chemistry, 2013, 21 (11), 2856-2867.
• W. H. Lin, S. Y. Hsieh, S. C. Yen, C. T. Chen, T. K. Yeh, T. Hsu, C. T. Lu, C. P. Chen, C. W. Chen, L. H. Chou, Y. L. Huang, A. H. Cheng, Y. I. Chang, Y. J. Tseng, K. R. Yen, Y. S. Chao, J. T. Hsu, W. T. Jiaang. "Discovery and evaluation of 3-phenyl-1H-5-pyrazolylamine-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3)." Bioorganic & medicinal chemistry, 2011, 19 (14), 4173-82.
• S. Y. Hsieh, M. D. Jan, L. N. Patkar, C. T. Chen, C. C. Lin. "Synthesis of a carboxyl linker containing Pk trisaccharide." Carbohydrate research, 2005, 340 (1), 49-57.
• K. C. Lu, S. Y. Hsieh, L. N. Patkar, C. T. Chen, C. C. Lin. "Simple and Efficient per-O-Acetylation of carbohydrates by lithium perchlorate catalyst." Tetrahedron, 2004, 60 (40), 8967-8973

• S. H. Wang, S. C. Y. J. Tung, C. W. Kuo, Y. H. Tai, S. Y. Hsieh, K. L. Lee, S. R. Hsiao, J. F. Sheen, J. C. Hsu and P. K. Wei. “Multichannel Nanoplasmonic Platform for Imidacloprid and Fipronil Residues Rapid Screen Detection Biosensors and Bioelectronics or its open access mirror” Biosens. Bioelectron. 2020, 170, 112677.
• S. H. Wang, C. W. Lee, M. Y. Pan, S. Y. Hsieh, F. G. Tseng, and P. K. Wei. “Chromatogram analysis on revealing aggregated number and location of gold nanoparticles within living cells.” Plasmonics, 2015, 10(4), 873-880.
• W. H. Lin, T. K. Yeh, W. T. Jiaang, K. J. Yen, C. H. Chen, C. T. Huang, S. C. Yen, S. Y. Hsieh, L. H. Chou, C. P. Chen, C. H. Chiu, L. C. Kao, Y. S. Chao, C. T. Chen, and J. T. A. Hsu. & Chiu, C. H. “Evaluation of the antitumor effects of BPR1J-340, a potent and selective FLT3 inhibitor, alone or in combination with an HDAC inhibitor, vorinostat, in AML cancer.” PloS one, 2014, 9(1), e83160.
• S. H. Wu, S. Y. Hsieh, K. L. Lee, R. H. Weng, A. Chiou, and P. K. Wei, “Cell viability monitoring using Fano resonance in gold nanoslit array.” Applied Physics Letters, 2013, 103(13), 133702.
• W. H. Lin, J. T. A. Hsu, S. Y. Hsieh, C. T. Chen, J. S. Song, S. C. Yen, T. Hsu, C. T. Lu, C. H. Chen, L. H. Chou, Y. N. Yang, C. H. Chiu, C. P. Chen, Y. J. Tseng, K. J. Yen, C. F. Yeh, Y. S. Chao, T. K. Yeh, and W. T. “Discovery of 3-phenyl-1H-5-pyrazolylamine derivatives containing a urea pharmacophore as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3).” Jiaang, Bioorganic & medicinal chemistry, 2013, 21(11), 2856-2867.